• Home
  • About
  • Diagnostics
    • Ophthalmological
      • Overview
      • IgE Test
      • Lactoferrin Test
    • Other Areas
      • New Test Development
  • Investors
    • Company Info
    • Press Releases
    • Presentations
    • SEC Filings
    • Corporate Governance
    • FAQ
  • Contact

AXIM Biotechnologies Receives Medical Device Manufacturing License

by Kyle | May 29, 2024 | Press Release

State of California Department of Public Heath Food and Drug Branch Issues the Company a License for Manufacturing of its Diagnostic Assays SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the...

VIDEO: AXIM® Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

by Kyle | Mar 27, 2024 | Press Release

Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...

AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation

by Kyle | Feb 20, 2024 | Press Release

The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) — via NewMediaWire –  AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”),...

AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production

by Kyle | Dec 20, 2023 | Press Release

Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM...

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

by Kyle | Aug 1, 2023 | Press Release

Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO–(BUSINESS WIRE)–AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
« Older Entries

About

Diagnostics

Investors

Contact

Success!

Subscribe

  • Follow
  • Follow